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Summary.-Male DBA2 mice were given 106 P-388 leukaemic cells i.p. and cimeti-
dine (CMT) at 100 mg/kg 1 day for 10 days, or as a single 100mg/kg injection 30 min
before cyclophosphamide (CTX). CMT significantly prolonged the survival of groups
of mice receiving 50, 100 and 200 mg/kg of CTX 3 days after tumour inoculation.
Median survival increased by 5-5 days (P <0-05), 10 days (P <0.05) and 13 days (P <
0.05) respectively. The addition of CMT had the effect of roughly doubling the CTX
dose, without increasing the lethality. CMT produced the only long-term survival
seen in the study (1-2/10) CMT alone had no apparent antitumour activity. CMT
significantly prolonged mean pentobarbital sleep to 28-6-60 min vs only 10 min for
phenobarbital treated mice. Both CMT regimens increased the plasma concentration
time products for CTX-induced metabolites (NBP) by about 1-3 fold (in contrast to
a 33% reduction with phenobarbital). On average the single-dose CMT regimen
produced the greatest effect on survival, on pentobarbital sleep duration and on
total NBP reactive species. Probable mechanisms for the CMT-CTX interaction
include competitive microsomal enzyme inhibition and/or acutely depressed
hepatic blood flow. Caution should be used in combining CMT with full doses of CTX
and any other highly metabolized antineoplastic agents in man.
CYCLOPHOSPHAMIDE (CTX) is a clinically
important anticancer drug which must be
metabolized in vivo to its alkylating
species to show antitumour activity in
animals and man (Brock et al., 1971;
Sladek, 1972). The initial step of the
complex metabolic process involves
enzymatic hydroxylation in the 4 position
of the oxazophosphorine ring, and is
mediated by mixed-function oxygenase;
microsomal enzymes concentrated in the
mammalian liver. A variety of other
drugs used clinically may interact with
these enzyme systems and thereby alter
the metabolic activation and antitumour
effectiveness of CTX (Hart & Adamson,
1]969).
Cimetidine (CMT) is a blocker of the H2
histamine receptor and is used in the
treatment of ulcer disease (Henn et al.,
1975). Recently, CMT has been shown to
depress the clearance of a number of
microsomally metabolized drugs in rodents
(Desmond et al., 1980a; Pelkonen &
Puurunen, 1980) and in man (Desmond
et al., 1980b; Klotz et al., 1979; Serlin et al.,
1979; Jackson et al., 1981).
Because CMT can alter drug metabolism
and is commonly used in cancer patients,
we studied the possibility of interaction
between CMT and CTX in leukaemic mice.
Our results show significant cimetidine-
induced enhancement of both the anti-
tumour effects of CTX and the total of
alkylating metabolites produced by a
single large CTX dose.
METHODS
Mice.--Six to 8-week-old male DBA2 mice
weighing , 28 g were used in all experiments.
For survival studies mice were divided into
treatment groups of 10 and housed 5 per cage
on standard wood-chip bedding, and were
given acid drinking water anid food adR. T. DORR AND D. S. ALBERTS
libitum. Animals were acclimilatized at least 2
weeks before study.
Tumour. P-388 leukaemic cells were col-
lected fresh from the ascitic fluid of 3-4 pi:e-
treated inice. The cells wvere pooled in McCoy's
5A medium (Crand Island Biological Co..
Grand Island, N.Y.) and adjusted for i.p.
injection to a concentration of 106 cells/mm3.
The tumour line as originally obtained from
Dr Robert Struck (Southern Researeh Insti-
tute, Birming,ham, Ala.) and kept viable by
serial ascites transplantations at wNeekly
intervals. The P-388 tumour was selected for
this study due to its greater sensitivity to
anticancer drugs (Venditti, 1975).
Drugs and chemicals. Cyclophosphamnide
in parenteral powdered form (Mead Johnson
and Co., Evansville, Ind.) was reconstituted
in sterile water for injection wvith-out preserva-
tive, and brought to final concentrations of 5,
10 and 20 mg/ml for i.p. injection. Each dose
wvas given at a constant volume of 0 01 rnl/g
mouse weight. Cimetidine (CMT) in parenteral
solution (Smith, Kline & French, Philadel-
phia, Pa) was further diluted in preservative
free 0.89% NaCl to a final concentration of
25 ing/ml for i.p. injection at a dose of 100
mg/kg/dav. Sodium phenobarbital in parent-
eral solution (Winthrop Laboratories. Newr
York, N.Y.) was added to slightly acidified
sterile water up to a concentration of 0 5 mg/
ml and exchanged for the routinely used acid
drinking water (McPherson, 1963).
Assessment of hepatic rnicrosomal enzyme
activity was carried out using sleep duration
induced by parenteral sodium pentobarbital
(Abbott Laboratories, North Chicago, Ill.)
diluted to a concentration of 5 mg/ml in
0 89% preservative free NaCl. Each dose
was given i.p. at a volume of 0.01 ml/g mouse
wveight.
For quantitation of total CTX, the alky-
lating metabolite, 4-(p-nitrobenzyl)-pyridine
(NBP) wvas obtained in powdered form (98%
pure) from Aldrich Chemical Co., Milwaukee,
Wis. and diluted to a 50/0 wN-/v concentration.
A standard curve for alkylating activity wNas
constructed using serial dilutions of parent-
eral mechlorethamine (Merck. Sharp and
Dohme, West Point, Pa.). Other chemicals
used in the assay were reagent grade.
Administration schedule of chemnotherapeutic
agents-.For assessing survival, 3 dose levels
of CTX were used: 50, 100 and 200 mg/kg.
Each dose was given i.p. on the 3rd day
after i.p. administration of 106 P-388 cells on
Day 1. Twro schedules of concomitant CMT
administration were evaluated: a 10-day
load, 100 mg/kg i.p. Days -4 to +6 (all 3
CTX dose levels) and a single 100mg/kg i.p.
injection 30 min before the CTX (100 and
200 mg/kg only) on Day 3. A phenobarbital-
treated group (CTX 200 mg/kg only) wAras
placed on the phenobarbital drinking water
on Days -6 to +6. Control groups (n=10
each) included: (1) CTX only at the 3 speci-
fied doses i.p. on Day 3, (2) CMT only at 100
mg/kg/day i.p. as a 10-day load and (3) 0.890/%
saline only administered 01 ml i..p and also
as a 10-day load (no CTX, no CMT). One
treatment group (CTX 200 mg/kg) received
both the i.p. CMT and the p.o. phenobarbital
as described above.
In 4 other groups of animals (n,=5 each)
microsoinal enzyme induction by phenobarbi-
tal or CMT was assessed by sleep duration
studies followving an i.p. pentobarbital dose
of 45 mg/kg. Treatment groups included
control, phenobarbital loaded, cimnetidine
loaded, and single-dose cimetidine treated
animals.
Survival N as assessed by observing for
death at 12 h intervals. Survival wvas statist-
ically analysed by computer., primarily using
a generalized Wilcoxon test (Gehan, 1965). In
some instances the logrank test was added
for comparison of survival patterns, since
the Wilcoxon test censors data in favour of
early survival differences, wNhereas the log-
rank method is wAeighted in favour of detect-
ing differences in long-term survival (Mantel.
1966).
(Cyclophosphamnide alkylating mnetabolites by
NBP Assay. Four groups of animals (n =40
each) were used to study the production of
alkylating metabolites of CTX after i.p.
injection of 200 mg/kg. This high dose was
historical convention and was necessitated by
the sensitivity limits of the assay. This dose
is close to the LD10 (in BDF1 mice) of - 250-
300 mg/kg (Hill, 1975). At serial times after
CTX, groups of 4 mice were lightly anaesthet-
ized with ether and the total available blood
collected by cardiac puncture into iced
heparinized centrifuge tubes. The pooled
plasma (- .5 ml) w-as separated by centri-
fugation at 2000 rev/min for 10 min. and
stored frozen at -20°C for analysis later on
the day of collection.
The NBP assay wNas a modification of the
colorimetric method of Friedman & Boger
(1961) as described by Alberts & van Daalen
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FIG. 1. Survival curves for groups of mice given 3 (loses of cyclophosphamide (CTX): 50 (a), 100 (b)
and 200 mg/kg (c) on Day 3 (0) compared to the same schedules plus a 10-day load of cimetidine
(CMT) 100 mg/kg i.p. Days -4 to +6 (A). 106 P-388 leukaemia cells are given i.p. on Day 0.
Statistical analysis by Wilcoxon method, gives P for differences as follows: a, 0 045; b, 0 005;
c, 0(02 logrank tests for C gives P=0(05.
W'etters (1976). Absorbances wNere read oIn a
Gilford inicroflow cell spectrophotometer set
at 540 nm. Readings were taken 80 s after
production ofthe blue alkylator chromophore.
as specified in the modified assay. The need
to use lml plasma samples (pooled from 4
animals) did not allow duplicate analysis of
individual samples. The levels were then used
to generate plasma-time decay curves for
NBP. The areas under these decav curves
(AUC) wrere calculated using the trapezoidal
rule.
RESULTS
The addition of CMT to all 3 CTX
doses (50, 1]00 and 200 mg/kg) significantly
prolonged the survival of the leukaemic
mice, (Fig. I and Table I). Median survival
increased by 5-5 days ((P < 0.005) 7 0 days
(P < 0 05) and by 13-0 days (P < 0 05) for
the 3 CTX doses respectively. There was
no apparent antitumour effect for CMT
alone at 100 mg/kg i.p. for 10 days. Sur-
vival was identical to a saline-treated
group (median survival 13 days). Long-
term survival was produced only by the
addition of CMT, and an advantage was
seen for the single pre-CTX 100 mg/kg
CMT administration. This wassignificantly
better than 10 days of CMT treatment at
this CTX dose level (P = 0'0001, Fig. 2).
At the highest CTX dose (200 mg/kg
i.p.) early treatment deaths cancelled
CMT effects on median survival. None
the less, long-term survival was still pro-
duced only in groups receiving concomit-
ant CMT: 10% long-term survival in the
single-dose CMT group and 20% long-term
survival in the 10-day CMT group. The
addition of oral phenobarbital at this high
CTX dose did not alter survival. The
further addition of CMT to phenobarbital
and CTX tended to increase median
survival (from 18 days to 28 days) but!
this difference was not statistically
significant.
Thus the most effective treatments in
this study were 100 mg/kg CTX plus the
single CMT injection (better survival than
with 200 mg/kg CTX alone; P < 0-02
Wilcoxon, < 0*05 logrank Fig. 3) and the
200 mg/kg CTX plus either single-dose or
10-day CMT; the latter producing the
highest long term survival rate (Fig.
IC'). (The logrank P-values were con-
sistently higher than the Wilcoxon values.)
This confirms that early survival was most
I
I
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TABLE I.-Antitumour s?trvival in DBA leukaemic mice (106 P-388 leukaemia cells
on Day 0)
Other
treatment
Control
Control
Control
Control
Phenobarb §
Phenobarb
Long-term survivors Median survivalt
CMT doset (10 treated) (days)
0 13
10 0 13
0 19-5
10 0 25*
0 24
10 0 31**\ **
1 0 35**
0 18
0 20
10 0 28
1 0 29***
10 2 33
t Survival differences arecompared to theappropriate control group receiving CTX
only (unless otherwise indicated). For all other comparisons (no symbol) P>0-1.
*P<0.05, ** P <0405, *** 0.05<P< 0-1.
t 101 = 00mg/kg/day for 10 days.
§ 0-5 mg/ml in drinking water
1 =single dose of 100/mg/kg.j
1.0
.9
.8
.7
C
> .6
C .5 0
.-W a.
0 6 12 18 24 30 36 42 48 0 6 12 18 24 30 36 42 48
Days Days
FIG. 2.-A comparison of the antileukaemic FIG. 3.-A comparison ofthe survival advant-
advantage (in terms of survival) of adding age of combining 100 mg/kg CTX with a
a single CMT dose (100 mg/kg) i.p. 30 min single 100 mg/kg CMT injection (A) over
before 100 mg/kg CTX (A) to the same double the CTX dose (200 mg/kg) without
CTX dose given alone (A). P< 0-0001. CMT (0).
effected by CMT. This also demonstrates
that CMT does not enhance CTX lethality,
since at 200 mg/kg of CTX, CMT actually
prevented early treatment deaths (those
occurring before Day 13, the median
survival day in untreated control animals).
The same pattern ofCMT augmentation
was evident in the production of CTX
alkylating moieties as detected by the
NBP assay (Table II). Most alkylating
CTX dose
(mg/kg)
50
50
100
100
100
200
200
200
200
200
cn Co
0
2
a.
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TABLE II. Areas under the NBP aklylat-
ing-activity curve.
Groups (of 4 mice)
CTX 200 mg/kg i.p.
CTX 200/kg i.p.+CMT 10-day
CTX 200/kg i.p. + Phenobarb
CTX 200/kg i.p. + CMT x 1
(30 min before CTX)
HN2 equivalents,
integrated
(gg/ml min)
5985
7560
4090
8075
Time Post Cyclophosphamide Injection (min)
1FiC. 4. A concentration versus time plot of
CTX-produced NBP alkylating activity for
CTX (200 mg/kg, * * and for the?
same schedule with 100 mg/kg CMT given
ip. as a 10-day load (O-- 0).
Time Post Cyclophosphamide Injection (min)
FIG. 5. A concentration versus time plot of
CTX-produced NBP alkylating activity in
phenobarbital-pretreated mice receiving
200 mg CTX i.p. (A * -A) and those
receiving the same CTX dose combined
with a single injection of CMT 30 min
earlier (U - - *). Note the delay to peak
activity for CMT-treated animals com-
pared with the rapid peak produced by
phenobarbital pretreatment. Activity in
CMT-treated mice remains substantially
higher thereafter than those with CTX
alone (* Fig. 4) and especially
higher than in phenobarbital-pretreated
mice (Fig. 5).
Group
Normal mice
Phenobarbital loa(d
CMT (10-day load)
CMT (single dose, 10 mill
before)
Sleep time (min± s.d.)
28-6+4-1
105+3 9
62 *2+ 35 - 9
111 8+23-5
activity was seen in the groups receiving
concomitant CMT. In contrast, the addi-
tionofphenobarbitalsubstantiallyreduced
the area under the NBP curve to about
2/3 the control quantities. Figs 4 and 5
show the decay curves for NBP in the
4 groups. Phenobarbital caused early high
peak NBP activity which diminished
rapidly. Both CMT-pretreated groups
showed prolongation of CTX-associated
NBP activity.
CMT also produced major changes in
pentobarbital induced sleep (Table III).
The single i.p. CMT injection (10 min
before pentobarbital) was most potent,
increasing the average sleep time almost
4-fold. Animals loaded 10 days on i.p.
CMT (last treated 4 h before pentobar-
bital) had sleep times increased about
2-fold. The variability in each instance
however was relatively large. Pheno-
barbital-pretreated animals showed sub-
stantial enzyme induction, sleeping only
one-third as long as the control animals.
DISCUSSION
Cimetidine, an H2 histamine blocker, is
commonly used in the acute and chronic
management of gastric and duodenal
ulcer, as well as in other pathological
hypersecretory conditions [e.y. the Zol-
linger Ellison syndrome (McCarthy et al.,
1977)]. In addition to the drug interaction
seen in this study, CMT can cause a
number of uncommon suppressive haem-
atological reactions, including agranulo-
cytosis (Chang & Morrison, 1979; Posnett
et al., 1979) and pancytopenia (DeGalocsy
& Van Ypersele de Strihou, 1979); as well
as consistent immuno stimulation. The
latter mechanism involves augmented
lymphocyte blastogenesis (Gifford et al.,
TABLE III.-Pentobarbital sleep times
394R. T. DORR AND D. S. ALBERTS
1981) and CMT blockade of suppressor
T-cell activation, normally mediated
through H2 histamine receptors. CMT
suppresses both antibody formation
(Shearer et al., 1972) and T-mediated
cytolysis (Plaut et al., 1973). Recently,
CMT has been shown to prevent the
metastatic spread of 3LL adenocarcinoma
and to extend survival in mice (Osband
et al., 1981). Inactivation of suppressor
cells by CMT indicated a direct immuno-
logical tumoricidal role for the drug.
Simultaneously Gifford et al. (1981)
showed that CMT significantly reduces
tumour formation and increases the sur-
vival of mice given the EL4 ascites lym-
phoma or the Mc43 fibrosarcoma. No
direct in vitro cytoxicity of CMT was
seen. This is consistent with our conclus-
ion that CMT alone had no antitumour
activitv.
The most effective immunostimulative
CMT dose in Gifford's study (100 mg/kg/
day orally) is identical to the i.p. dose
used in the present report. While this
dose is much larger than CMT doses clinic-
ally recommended in man (up to 20 mg/
kg/day), peak murine plasma levels from
this dose are comparable to levels obtained
in man following standard doses (Gifford
et al., 1981). Thus, the CMT dose used in
the current study should be of biological
significance in man.
In addition to the direct haemotological
and immunological effects of CMT, the
drug also depresses the clearance of a
variety of other drugs whose elimination
depends on microsomal metabolism. The
list of drugs so effected includes the sed-
atives chlordiazepoxide (Desmond et al.,
1980b) and diazepam (Klotz et al., 1979)
the oral anticoagulant warfarin (Serlin
et al., 1979) the methylxanthines caffeine
(Desmond et al., 1980a) and theophylline,
(Campbell et al., 1981; Jackson et al., 1981)
as well as the hepatic-clearance indicator
drugs, antipyrine (Klotz et al., 1979) and
aminopyrine (Desmond et al., 1980a).
Furthermore, Pelkonen & Puurunen (1980)
found that CMT pretreatment in rats
caused significant prolongation of hexo-
barbital sleep and inhibition of amino-
pyrine N-demethylation without altering
benzo(a)pyrene hydroxylation. In addition
pretreatment did not induce hepatic drug
metabolism. This pattern is consistent
wTith non-specific CMT inhibition of the
cytochrome microsomal enzyme systems
including the P-448 and P-450 fractions.
Spectral analysis indicates a Type II
inhibitory pattern for CMT (believed to be
a general property of compounds with a
"sterically-accessible" nitrogen atom in-
cluding imidazoles like CMT [Mailman
et al., 19741).
Cyclophosphamide is an antitumour
drug which exerts its cytoxic effects via
the generatioin of alkylating metabolites,
principally phosphoramide mustard
(Struck et al., 1975). Activation ofthe drug
is initiated by 4-hydroxylation, process
predominantly due to hepatic microsomal
mixed-function oxidases (Cohen & Jao,
1970). Phenobarbital, a known inducer of
diverse hepatic microsomal activities
(including P-450), has demonstrated no
significant CTX interactions in man (Jao
et al., 1972). Yet in experimental animals
in this study and others (Alberts et al.,
1976; 1978) the addition of this enzyme
inducer markedly reduces thetotalamount
of alkylating metabolites from CTX, and
its antitumour effects. It should be borne
in mind, however, that phenobarbital
administration also increases hepatic size
and blood flow (Yates et al., 1978) and
bile flow (Klaassen, 1]969).
Conversely, experimental microsomal
enzyme inhibitors such as SKF-525a
(diethylaminoethyldiphenyl valerate)
depress hepatic blood flow (Hakim &
Fujimoto, 1971) and can reverse pheno-
barbital induction and restore CTX anti-
tumour activity (Alberts et al., 1976).
When used alone, SKF-525a reduced CTX
lethality in animals without altering its
antitumour effectiveness (Hart & Adam-
son, 1969). This inhibitor can also pro-
long the half-life of CTX in mice (Bus
et al., 1973) an effect identical to the
CMT-CTX interaction in the present
study. CMT also similarly reduiced CTX
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lethality in this study while substantially
enhancing both early and late tumour
suirvival.
Thus we have deinonstrated consisteint
CMT-induced enhancement of t,he anti-
tumour effect of CTX in mice. CMT also
significantly prolonged phenobarbital
sleep, as in the findings of Pelkonen &
Puurunen (1980). We were not, able to
detect a direct, antitumour effect of CMT
in the P-388 leukaemia system. OIn
average the addition of CMT as a 10-day
i.p. load had the survival prolongation
effect of roughly doubling the CTX dose
(Table I). Also CMT inclusion producedthe
only long-term survival. In this respect the
10-day CMT load did not dramatically
increase survival over a single CMT
injection 30 min before CTX. Similarly a
single CMT injection produced the largest
amount of NBP alkylating species (Table
II), and the greatest prolongation of
pentobarbital sleep. A significant CMT
effect on liver size or total microsomal
enzyme mass is not consistent with these
results. At least two other reasonable
explanations remain for the augmented
CTX effects seen in this study: (1) a
competitive alteration or blockade of
substrate (CTX) sites on hepatic P-450
microsomal enzymes and (2) a significant
CMT-induced reduction in liver blood flow,
slowing the hepatic extraction of CTX A
reduction in liver blood flow has been
described for the other classic enzyme
inhibitor SKF-525a in animals (Marchand
& Brodeur, 1970) and in man; CMT has
been shown to depress liver blood flow by
up to 25% after acute administration and
by 3300 followving chronic oral administra-
tion (Feely et al., 1981).
The results of the NBP-CTX assays are
difficult to assess since the assay is not
specific for cvtotoxic CTX metabolites.
Thus inactive as well as active metabolites
and parent drug will be quantified. None
the less, our analysis demonstrated pro-
longed retention of NBP-reactive species
in CMT-treated mice (Figs 4 & 5). In
additioni phenobarbital depressed the
formation of total NBP-reactive species
by about one-third (Table II). This is
consistent with pharmacokinetic results
uising a more specific NPB-reactive, thin-
layer chromatography in which a 270%
reduction in the AUC for phosphoramide
mustard was obtained following the com-
bination of CTX with phenobarbital
(Alberts et al., 1978). The more rapid CTX
decay in the presence ofphenobarbital had
also been described earlier (Field et al.,
1972; Bus et al., 1973). It is possible that
CMT might have even greater effects on
orally administered CTX, for which hepa-
tic extraction is significant following
absorption. InthisregardCMThasrecently
been shown to substantially increase the
bioavailability oforalpropranolol, another
highlyextracteddrug(Heagertyetal.,1981).
The metabolism of a number of other
clinically used anticancerdrugsis mediated
to some degree by microsomal enzymes.
These include procarbazine, dacarbazine,
doxorubicin, hexamethylmelamine and
the nitrosoureas. For one such compound,
the nitrosourea carmustine (BCNU) a
similar pattern to CTX is emerging:
phenobarbital pretreatment in rats des-
troyed the antitimour activity of BCNU
(Levin et al., 1979) while concurrent CMT
markedly enhanced BCNU-induced mar-
row depression in a single patient (Selker
et al., 1978). It should also be borne in
mind, however, that drug metabolism and
microsomal enzyme activity may be
inhibited by the presence of tumour
(Rosso et al., 1971) or by the antitumour
drug itself (e.g. CTX in Marinello et al.,
1981).
In conclusionwehavedemonstratedthat
CMT induces (1) statistically significant
augmentation of CTX antitumour effects
in leukaemic mice and (2) substantial
increases in NBP alkylating species follow-
ing a large CTX dose. It is possible that
similar CMT-induced CTX augmentation
may be seen in man. Thus, until more
definitive studies are completed, caution
should be exercised whenever cimetidine
is combined with full doses of CTX or any
other microsomallv metabolized anti-
neoplastic drug.
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